甲磺酸达比加群酯，872728-81-9

中文名称甲磺酸达比加群酯中文同义词达比加群脂MESYLATE;甲磺酸达比加群酯100G;甲磺酸达比加群酯对照品;3-[[[2-[[[4-[[[(己氧基)羰基]氨基]亚氨甲基]苯基]氨基]甲基]-1-甲基-1H-苯并咪唑-5-基]羰基](吡啶-2-基)氨基]丙酸乙酯甲磺酸盐;甲磺酸达比加群酯;达比加群酯甲璜酸盐;达比加群酯甲磺酸盐;达比加群酯甲磺酸英文名称DabigatranEtexilateMesylate英文同义词Dabigatranetexilatemesylate;(Z)-ethyl3-(2-(((4-(N'-((hexyloxy)carbonyl)carbamimidoyl)phenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoatemethanesulfonate;Ethyl3-(2-(((4-(N-((hexyloxy)carbonyl)carbamimidoyl)phenyl)amino)methyl)-1-methyl-N-(pyridin-;Dabigatranetexilatemesylate,Pradaxa;ethyl3-(2-(((4-(N-((hexyloxy)carbonyl)carbamimidoyl)phenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoatemethanesulfonate;DabigatranMesylateReference;Dabigatranmesylate;N-[[2-[[[4-[[[(Hexyloxy)carbonyl]amino]iminomethyl]phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-beta-alanineethylestermonomethanesulfonatsupplierinChinCAS号872728-81-9分子式C35H45N7O8S分子量723.85

简介

甲磺酸达比加群酯是应用于临床的直接凝血酶抑制剂，是一种新型口服抗凝药。其作用机理是通过可逆性强效竞争结合凝血酶的纤维蛋白特异结合位点，使纤维蛋白生成受阻，从而抑制血栓的形成。

应用

甲磺酸达比加群酯是血液系统用原料药；抗凝血药物；可用于有非瓣膜性心房颤动患者中减低中风和全身栓塞的风险Chemicalbook；达比加群酯是一种新型的合成的直接凝血酶抑制剂，是dabigatran的前体药物，属非肽类的凝血酶抑制剂。